Eagle Pharmaceuticals, Inc. Reports Third Quarter 2018 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/19/2026
- Wall St rises as yields ease, Moderna lifts healthcare stocks
- U.S. Treasury doubles buyback operation size for long-dated bonds
- Marvell shares jump after giving Google warrants amid custom chip deal
- U.S. debt tops $40 trillion
- Nvidia credit risk gauge hits new peak as SoftBank readies record bond issue
- Marvell issues Google warrant tied to custom chip deal
- Tech selloff weighs down Wall Street as bond yields climb
- FOMC minutes from July 28-29th meeting
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
Eagle Pharmaceuticals (EGRX) PT Lowered to $64 at RBC Capital
November 2, 2018 7:01 AM EDTRBC Capital analyst Randall Stanicky lowered the price target on Eagle Pharmaceuticals (NASDAQ: EGRX) to $64.00 (from $84.00) while maintaining an Outperform rating.
Stanicky said results place a spotlight on recent pipeline setbacks and outlook.
... MoreEagle Pharmaceuticals (EGRX) Misses Q3 EPS by 7c, Revenues Miss
November 1, 2018 6:51 AM EDTEagle Pharmaceuticals (NASDAQ: EGRX) reported Q3 EPS of $0.91, $0.07 worse than the analyst estimate of $0.98. Revenue for the quarter came in at $51.3 million versus the consensus estimate of $55.23 million.
While we were disappointed in the outcome of the fulvestrant trial, we believe in the strength of the remaining products in our pipeline and... More
